Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Default user image.

Jan Nilsson

Professor

Default user image.

Use of Vascular Assessments and Novel Biomarkers to Predict Cardiovascular Events in Type 2 Diabetes : The SUMMIT VIP Study

Author

  • Angela C Shore
  • Helen M Colhoun
  • Andrea Natali
  • Carlo Palombo
  • Faisel Khan
  • Gerd Östling
  • Kunihiko Aizawa
  • Cecilia Kennbäck
  • Francesco Casanova
  • Margaretha Persson
  • Kim Gooding
  • Phillip E Gates
  • Helen Looker
  • Fiona Dove
  • Jill Belch
  • Silvia Pinnola
  • Elena Venturi
  • Michaela Kozakova
  • Isabel Goncalves
  • Jasmina Kravic
  • Harry Björkbacka
  • Jan Nilsson

Summary, in English

OBJECTIVE: Cardiovascular disease (CVD) risk prediction represents an increasing clinical challenge in the treatment of diabetes. We used a panel of vascular imaging, functional assessments, and biomarkers reflecting different disease mechanisms to identify clinically useful markers of risk for cardiovascular (CV) events in subjects with type 2 diabetes (T2D) with or without manifest CVD.

RESEARCH DESIGN AND METHODS: The study cohort consisted of 936 subjects with T2D recruited at four European centers. Carotid intima-media thickness and plaque area, ankle-brachial pressure index, arterial stiffness, endothelial function, and circulating biomarkers were analyzed at baseline, and CV events were monitored during a 3-year follow-up period.

RESULTS: The CV event rate in subjects with T2D was higher in those with (n = 440) than in those without (n = 496) manifest CVD at baseline (5.53 vs. 2.15/100 life-years, P < 0.0001). New CV events in subjects with T2D with manifest CVD were associated with higher baseline levels of inflammatory biomarkers (interleukin 6, chemokine ligand 3, pentraxin 3, and hs-CRP) and endothelial mitogens (hepatocyte growth factor and vascular endothelial growth factor A), whereas CV events in subjects with T2D without manifest CVD were associated with more severe baseline atherosclerosis (median carotid plaque area 30.4 mm2 [16.1-92.2] vs. 19.5 mm2 [9.5-40.5], P = 0.01). Conventional risk factors, as well as measurements of arterial stiffness and endothelial reactivity, were not associated with CV events.

CONCLUSIONS: Our observations demonstrate that markers of inflammation and endothelial stress reflect CV risk in subjects with T2D with manifest CVD, whereas the risk for CV events in subjects with T2D without manifest CVD is primarily related to the severity of atherosclerosis.

Department/s

  • EXODIAB: Excellence of Diabetes Research in Sweden
  • Department of Clinical Sciences, Malmö
  • Internal Medicine - Epidemiology
  • EpiHealth: Epidemiology for Health
  • Cardiovascular Research - Translational Studies
  • Cardiovascular Research - Immunity and Atherosclerosis
  • Diabetic Complications
  • Genomics, Diabetes and Endocrinology
  • Cardiovascular Research - Cellular Metabolism and Inflammation

Publishing year

2018-10

Language

English

Pages

2212-2219

Publication/Series

Diabetes Care

Volume

41

Issue

10

Document type

Journal article

Publisher

American Diabetes Association

Topic

  • Cardiac and Cardiovascular Systems
  • Endocrinology and Diabetes

Status

Published

Research group

  • Internal Medicine - Epidemiology
  • Cardiovascular Research - Translational Studies
  • Cardiovascular Research - Immunity and Atherosclerosis
  • Diabetic Complications
  • Genomics, Diabetes and Endocrinology
  • Cardiovascular Research - Cellular Metabolism and Inflammation

ISBN/ISSN/Other

  • ISSN: 1935-5548